Cannabis Science Awaits Full Biopsy Report As Newest Series of Photos Shows Cancer Lesion Evidently Completely Killed & Hair Re-growth Begins On New Healthy Skin From 2nd Self-Administering Cancer Patient
DENVER--(BUSINESS WIRE)--Feb 7, 2012 - Cannabis Science, Inc. (OTCBB:CBIS) a pioneering U.S. biotech company developing pharmaceutical cannabis (marijuana) products, is pleased to present the newest set of photographs showing evidence that the cancer cells appear to have been killed over the course of treatment from the 2nd self-administering cancer patient suffering from squamous cell carcinoma on her arm.
Later this month, the patient expects to have a full biopsy report on the now apparently healthy skin that has replaced the tumor. The tumor appears to have been expelled from below the surface, killed, and now fully healed. In these latest photos, not only does the lesion seem to have completely disappeared, but also hair is re-growing on the new healthy skin.
Cannabis Science first reported this patient in a news release dated January 19, 2012, this current series of photos show the disappearance of a biopsied squamous cell tumor after self- administration of topical cannabis extracts over a 3-month period.
You can view these photos on the Cannabis Science website www.cannabisscience.com and click the button “View Images of 2nd Self-Medicated Patient & The Apparent Success”
Cannabis Science is a patient oriented company. As such, we work closely with a number of patients suffering from a variety of illnesses including various cancers. Because of the global impact that cancer has on so many people, and the often-poor treatment outcome for patients, we have focused on cannabis extract-based treatment options for cancer. Cannabis Science provides the scientific foundation, and for some the formulations for numerous patients, suffering from a large variety of cancers, to make informed decisions to treat themselves with cannabis extracts properties, to treat disease and the symptoms of disease, as well as for general health maintenance.
About Cannabis Science, Inc.
Cannabis Science, Inc. is at the forefront of pharmaceutical grade medical marijuana research and development. The second formulations will address the needs of patients choosing to use concentrated cannabis extracts to treat their ailments. Eventually, all Americans will have access to a safe and effective FDA approved medicine regardless of which state they live in. To maintain that marijuana is a dangerous, addictive drug with no medical value is scientifically absurd. Cannabis medicines, with no effective lethal dose, are far safer than aspirin, acetaminophen, and most other OTC drugs that kill thousands of Americans every year. The Company works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce and commercialize phytocannabinoid-based pharmaceutical products. In sum, we are dedicated to the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance.
Forward Looking Statements
This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing works such as "anticipate," "seek," intend," "believe," "plan," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc. does not undertake any duty nor does it intend to update the results of these forward-looking statements.
Contact: Cannabis Science Inc.
Dr. Robert J. Melamede, President & CEO
Robert Kane, Investor Relations Management
Posted: February 2012